



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** November 6, 2009

**To:** Primary Clinical Research Associates

**From:** Alicia Elsing  
Protocol Development Coordinator

**Re:** N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

The Eligibility Checklist has been revised as follows:

<b>Form Title</b>	<b>Brief Description of Edit</b>
Eligibility Checklist	<ul style="list-style-type: none"><li>Deleted IRB approval/date verbiage</li></ul>

If you have any questions, please feel free to contact me at 507/538-3893.

Enclosure